> Alzheimer’s Research UK called on the British government to commit to spend 1% of the annual cost of dementia on research. The nonprofit calculates that dementia costs the U.K. economy £26 billion ($34 billion) a year. Statement
> 4D Pharma reported that its bacteria-based drug Thetanix was well tolerated by Crohn’s disease patients in a phase 1b trial. Release
> Galapagos dosed the first patient in a phase 2 osteoarthritis trial of GLPG1972. The event triggered a €9 million ($10.5 million) milestone payment from Servier. Statement
> Biofrontera began enrolling superficial basal cell carcinoma patients in a U.S. phase 3 trial of Ameluz. Release
> Sareum picked a TYK2-JAK1 inhibitor to move into preclinical development. Statement
> Microbiome startup A-Mansia added investors to its series A syndicate, bringing the total size of the round up to €18 million ($21 million). Release